NovoCare Pharmacy launched in March 2025 as Novo Nordisk's manufacturer-direct dispensing channel. Rather than routing through a retail pharmacy network, NovoCare ships Wegovy, Ozempic, Rybelsus, and insulin products directly to the patient's home or to a participating CVS retail location. The self-pay pricing available through NovoCare is substantially lower than retail list prices because Novo Nordisk absorbs distribution margins and sets a fixed direct price. In June 2026, the standard NovoCare self-pay price for Wegovy injectable is $349 per month for all doses up to 2.4 mg, down from a list price of $1,349 per month at retail pharmacies. Ozempic injectable runs $349 per month for doses up to 1 mg, and $499 per month for the 2 mg maintenance dose. Oral semaglutide tablets (Wegovy pill and Ozempic pill) are available at $149 per month for 1.5 mg and 4 mg doses.
Novo Nordisk insulin products are not part of the NovoCare Pharmacy self-pay channel. Instead, Novo Nordisk insulin (including NovoLog, Tresiba, Levemir, and Victoza) is available at $35 per month through the MyInsulinRx program, a separate savings card accepted at most retail pharmacies nationwide. The $35 monthly insulin cap pre-dates the Inflation Reduction Act: Novo Nordisk introduced it in 2023 alongside other manufacturers, and it covers up to 3 vials or 2 packs of pens per month for any combination of Novo Nordisk insulin products. Under the Inflation Reduction Act of 2022, Medicare Part D separately caps insulin at $35 per month for all Medicare beneficiaries, effective January 1, 2023. Commercially insured or uninsured patients access the $35 rate through the MyInsulinRx card rather than Medicare's statutory cap.
Semaglutide (Wegovy, Ozempic, Rybelsus) is in the second round of Medicare drug price negotiation under the Inflation Reduction Act. Negotiated Maximum Fair Prices for these drugs are scheduled to take effect January 1, 2027. Until then, Medicare patients access semaglutide through their Part D plan at standard plan pricing, subject to the $2,100 annual Part D out-of-pocket cap in 2026. NovoCare self-pay pricing is not available to Medicare beneficiaries. Medicare patients who need Wegovy for weight management should review Medicare GLP-1 weight loss coverage and whether they qualify for Medicaid income-based assistance through their state program.
What NovoCare Self-Pay Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same novocare self-pay can cost many times more at a hospital than at your local pharmacy:
2026 NovoCare Self-Pay Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| NovoCare Pharmacy direct (self-pay, no insurance) | $149 - $499/month depending on drug and dose | Wegovy injectable $349/mo; Ozempic injectable $349-$499/mo; oral tablets $149/mo. Not available for Medicare, Medicaid, TRICARE, or VA. |
| Pharmacy counter (retail list price, no savings) | $998 - $1,349/month (Ozempic and Wegovy injectable) | Retail list price without any discount program. GoodRx coupon typically saves 5-10% off list but still far above NovoCare direct pricing. |
| Medicare Part D (2026) | $0 - $200/month, capped at $2,100/year total | Ozempic covered for type 2 diabetes; Wegovy covered for cardiovascular risk reduction only (not weight loss alone). NovoCare self-pay is not available to Medicare beneficiaries. |
| Commercial insurance with NovoCare Savings Card | $25/month Ozempic; $0 - $25/month Wegovy (commercially insured only) | Separate from the self-pay NovoCare Pharmacy program. Savings cards require commercial insurance and are blocked for government insurance beneficiaries. |
| Novo Nordisk Insulin (MyInsulinRx, any retail pharmacy) | $35/month (up to 3 vials or 2 pen packs) | Covers NovoLog, Tresiba, Levemir, and other Novo Nordisk insulins. Available to commercially insured and uninsured patients. Medicare Part D insulin separately capped at $35/mo by statute. |
| Medicaid | $1 - $4/prescription with prior authorization | Ozempic typically covered for type 2 diabetes; Wegovy coverage varies by state. NovoCare self-pay programs are not available to Medicaid enrollees. |
NovoCare self-pay prices verified June 2026 via novocare.com. Retail list prices reflect 2026 GoodRx and pharmacy data. Part D ranges depend on your plan formulary tier and benefit-year position.
Source: NovoCare Pharmacy (novocare.com), CMS Part D 2026 benefit parameters, GoodRx 2026 price survey
Why Hospitals Charge So Much
Wegovy and Ozempic are self-administered outpatient drugs that rarely appear on inpatient hospital bills. When they do appear, it is usually because a patient was admitted while already on the medication and the hospital dispensed a dose from its inpatient pharmacy. Hospital inpatient pharmacies operate under a cost-plus markup structure: they pay the wholesale acquisition cost and then layer on facility fees, pharmacy handling charges, nursing administration fees, and overhead. A single Wegovy pen with a wholesale acquisition cost near $500 to $600 can be charged at $1,500 to $4,000 in an inpatient setting. That 3x to 7x markup is separate from anything NovoCare Pharmacy or a retail pharmacy would charge.
Patients who notice Wegovy or Ozempic on an itemized inpatient bill at several thousand dollars should request the specific NDC (National Drug Code) number from the hospital billing department. The NDC links directly to a wholesale acquisition cost figure published in the FDA drug database. Charges more than double the wholesale acquisition cost are common dispute targets. NovoCare Pharmacy pricing does not apply to inpatient hospital charges, but knowing what the manufacturer charges as a direct self-pay price establishes a useful price floor for billing disputes. Most commercial insurance contracts cap hospital pharmaceutical reimbursements at the outpatient pharmacy rate rather than the inpatient facility rate.
Patient Assistance Programs
Novo Nordisk operates two distinct assistance pathways. The NovoCare Pharmacy self-pay channel covers patients with no insurance or those choosing to pay out of pocket, at $349 to $499 per month. The Novo Nordisk Patient Assistance Program (PAP) goes further, offering free medication to income-eligible uninsured patients and certain Medicare patients who cannot afford their out-of-pocket costs. The commercial savings cards (Ozempic Savings Card, Wegovy Savings Offer) are a third tier available only to commercially insured patients. Income alone does not determine which tier applies; your insurance status is the first gating factor.
Patient assistance programs for NovoCare Self-Pay| Manufacturer program | Cost / Benefit | How to apply |
|---|
| NovoCare Pharmacy (Direct Self-Pay, No PAP Required) | Wegovy injectable $349/mo; Ozempic $349-$499/mo; oral tablets $149/mo. No income limit. No insurance required. | novocare.com/pharmacy.html |
| Novo Nordisk Patient Assistance Program (PAP) via NovoCare | Free Wegovy, Ozempic (uninsured only), Rybelsus, and insulin for income-eligible patients. Ozempic: income at or below 200% FPL for uninsured. All other medications: at or below 400% FPL. | novocare.com/diabetes/help-with-costs/pap.html |
| Ozempic Savings Card (Commercial Insurance Only) | $25/month for commercially insured patients. Not available for Medicare, Medicaid, TRICARE, or VA patients. | novocare.com/diabetes/products/ozempic/savings-offer.html |
| Wegovy Savings Offer (Commercial Insurance Only) | $0 - $25/month for commercially insured patients (varies by plan coverage). Not available for Medicare, Medicaid, TRICARE, or VA patients. | wegovy.com/savings |
| MyInsulinRx (Novo Nordisk Insulins at Retail Pharmacies) | $35/month for any combination of Novo Nordisk insulin products (up to 3 vials or 2 pen packs). Available to uninsured and commercially insured patients. Medicare insulin is separately capped at $35/mo by the Inflation Reduction Act. | novocare.com/diabetes/help-with-costs/help-with-insulin-costs/myinsulinrx.html |
| NeedyMeds Drug Discount Card | Variable discount at most US pharmacies. Often lower than GoodRx for some doses; check both before filling. | needymeds.org |
Manufacturer savings cards and the NovoCare Pharmacy self-pay program are not available to Medicare, Medicaid, TRICARE, or VA beneficiaries under federal anti-kickback statute (42 U.S.C. § 1320a-7b). Patients with government insurance who cannot afford their cost-sharing should apply for the Novo Nordisk Patient Assistance Program (PAP) instead, which is income-based and legally available to qualifying Medicare patients for most drugs. Note: Medicare Part D beneficiaries with coverage are no longer eligible for the Ozempic PAP as of 2026, because CMS reports 98 percent of Part D plans now cover Ozempic.
Source: Novo Nordisk NovoCare patient program pages (novocare.com), CMS anti-kickback guidance, NeedyMeds.org
Medicare Part D
Medicare Part D covers Ozempic for type 2 diabetes and Wegovy in limited cardiovascular-risk-reduction cases, but does not cover Wegovy for weight loss alone. Under the 2026 Part D benefit structure, your annual out-of-pocket spending across all covered Part D drugs is capped at $2,100. Once you hit that cap in a calendar year, you pay $0 for covered drugs for the remainder of the year. NovoCare Pharmacy self-pay pricing is not accessible to Medicare beneficiaries by law. The federal anti-kickback statute bars manufacturer-subsidized pricing from Medicare enrollees, even if the patient is willing to pay cash and skip insurance reimbursement.
Semaglutide (the active ingredient in Wegovy, Ozempic, and Rybelsus) is included in the second round of Medicare drug price negotiation under the Inflation Reduction Act of 2022. A negotiated Maximum Fair Price for semaglutide is scheduled to take effect January 1, 2027. That will create a federally capped Medicare rate directly comparable to what NovoCare Pharmacy currently charges self-pay patients. Medicare beneficiaries who struggle with semaglutide costs in 2026 should apply for the Medicare Part D Low Income Subsidy (Extra Help), which provides additional premium and cost-sharing assistance and is not subject to the anti-kickback restrictions that affect manufacturer savings programs.
Medicare insulin coverage is a separate matter with a clearer consumer benefit. Under the Inflation Reduction Act of 2022, Medicare Part D caps all covered insulin at $35 per month effective January 1, 2023. That Medicare cap applies to all covered insulin brands, including Novo Nordisk's Tresiba, NovoLog, and Levemir, without requiring patients to use a manufacturer savings card or a direct-pharmacy program. Medicare beneficiaries do not need and cannot use the MyInsulinRx program. The $35 monthly cap flows automatically through the Part D benefit once the insulin is on your plan's formulary tier.
Common NovoCare Self-Pay Billing Errors
Patients using NovoCare self-pay or savings programs encounter several common billing problems. Check for these before paying any unexpected bill:
- Insurance claim submitted for NovoCare Pharmacy fill despite self-pay certification. When you use NovoCare Pharmacy self-pay pricing, you certify you will not submit a claim to insurance. If the pharmacy submits a claim anyway, your insurer may retroactively demand the difference between the NovoCare price and what they paid.
- Savings card or manufacturer coupon declined because the pharmacy used the wrong BIN/PCN code for the NovoCare program. The Ozempic and Wegovy savings cards have specific BIN/PCN numbers that differ from the NovoCare Pharmacy direct-fill codes. Ask the pharmacist to rerun the claim with the correct card credentials.
- Medicare patient charged the NovoCare self-pay rate by a participating pharmacy, then denied reimbursement by Medicare. Medicare beneficiaries cannot use NovoCare self-pay pricing; if a pharmacy mistakenly processes the fill at NovoCare rates, Medicare will not reimburse it. Redirect to your Part D plan.
- Prior authorization not filed before the first fill, resulting in a claim denial at the commercial insurance rate. Most commercial plans require prior authorization for Wegovy and Ozempic before covering them. Paying the NovoCare self-pay rate is one workaround while the PA is pending.
- Introductory price ($199/month) applied past the two-fill limit or after the June 30, 2026 expiration date. The introductory rate is for new patients only, for the first two monthly fills, and expires June 30, 2026. After that, the standard $349 or $499 rate applies.
Frequently Asked Questions
What is NovoCare Pharmacy and how does the self-pay pricing work?
NovoCare Pharmacy is Novo Nordisk's manufacturer-direct dispensing channel, launched in March 2025. Self-pay patients with a valid prescription can enroll at novocare.com/pharmacy and receive Wegovy or Ozempic shipped to their home or to a CVS pickup location at prices far below retail. In June 2026, the standard self-pay rate is $349 per month for Wegovy injectable (all doses through 2.4 mg) and Ozempic injectable (doses through 1 mg). The Ozempic 2 mg dose runs $499 per month. Oral semaglutide tablets are $149 per month. New patients may qualify for a $199 introductory rate for the first two fills. No insurance required, but government insurance holders (Medicare, Medicaid, TRICARE, VA) are excluded by federal anti-kickback statute.
Can I use NovoCare self-pay pricing if I have Medicare?
No. Federal anti-kickback law (42 U.S.C. § 1320a-7b) bars Medicare, Medicaid, TRICARE, and VA beneficiaries from using manufacturer-subsidized pricing programs, including NovoCare Pharmacy self-pay rates and manufacturer savings cards. Medicare patients access Ozempic through their Part D plan, where the 2026 annual out-of-pocket cap is $2,100 for all Part D drugs combined. If you have Medicare and need additional help, apply for the Novo Nordisk PAP (income-based, legally available for most drugs) or apply for Part D Extra Help (Low Income Subsidy) at ssa.gov or 1-800-MEDICARE.
Is there a generic for Wegovy or Ozempic?
No generic or biosimilar semaglutide is available as of 2026. Semaglutide patents are expected to expire around 2031. Compounded semaglutide was widely available through 2025 during the FDA shortage period, but the FDA proposed removing semaglutide from the 503B bulk drug list in April 2026, which would end large-scale compounding once finalized. For patients who need a lower-cost GLP-1 receptor agonist, ask your prescriber whether tirzepatide products (Mounjaro, Zepbound) or liraglutide (Victoza, Saxenda) would be clinically appropriate, as formulary coverage varies by plan and may offer lower out-of-pocket costs.
How do I apply for the Novo Nordisk Patient Assistance Program for free Wegovy or Ozempic?
Visit novocare.com/diabetes/help-with-costs/pap.html or call 1-866-310-7549 to start the application. You will need your prescriber to co-sign the form, proof of household income (tax return or 4 pay stubs), proof of US residency, and documentation of your insurance status. For Wegovy and most Novo Nordisk medications, household income must be at or below 400 percent of the federal poverty level. For Ozempic specifically, uninsured patients must be at or below 200 percent FPL. Medicare Part D patients with Ozempic coverage are no longer eligible for the Ozempic PAP as of 2026. Processing takes 7 to 14 business days after a complete application is submitted.
What does the Novo Nordisk insulin cost without insurance in 2026?
Novo Nordisk insulin (including NovoLog, Tresiba, Levemir, and Victoza) is available at $35 per month through the MyInsulinRx savings card, accepted at most retail pharmacies nationwide. The $35 rate covers up to 3 vials or 2 packs of pens per month for any combination of Novo Nordisk insulin products. Uninsured and commercially insured patients are eligible. Register at novocare.com or by texting ENROLL to 24177. Medicare Part D patients do not use MyInsulinRx; Medicare separately caps all covered insulin at $35 per month under the Inflation Reduction Act of 2022, effective January 2023.
What if my insurance denies coverage for Wegovy or Ozempic?
Start by requesting a written denial notice from your plan and filing a formal coverage appeal within 60 days. Include a letter of medical necessity from your prescriber. Ask your prescriber to request a peer-to-peer review with the plan's medical director, which often reverses denials. If the internal appeal fails, escalate to an external independent review through your state's Department of Insurance, or through the Medicare IRE for Part D denials. While appeals are pending, NovoCare Pharmacy at $349 per month provides a cash-pay bridge. If appeals are ultimately denied, apply for the Novo Nordisk patient assistance program for free medication if your income is at or below the applicable federal poverty level threshold.
Does the Inflation Reduction Act IRA negotiation apply to Ozempic or Wegovy in 2026?
Not yet. The Inflation Reduction Act selected semaglutide (Ozempic, Rybelsus, Wegovy) for the second round of Medicare drug price negotiation. The Maximum Fair Price for semaglutide is not effective until January 1, 2027. In 2026, there is no IRA-negotiated Medicare rate for these drugs. Medicare patients pay based on their Part D plan's formulary tier, with the $2,100 annual out-of-pocket cap applying to all Part D spending. The 10 drugs with IRA-negotiated prices effective in 2026 include Eliquis, Jardiance, and Xarelto, but not semaglutide.
How does NovoCare Pharmacy direct pricing compare to GoodRx at retail chains?
NovoCare Pharmacy direct pricing consistently beats retail chain pricing with or without GoodRx coupons. At Costco (the lowest retail cash price among major chains), Wegovy injectable runs $1,280 to $1,380 per month, nearly four times the NovoCare direct price of $349. Ozempic at CVS with a GoodRx coupon runs $880 to $970 per month versus $349 at NovoCare for the same dose. Walgreens and Walmart hover near list price for GLP-1 drugs. For uninsured patients, NovoCare Pharmacy is the recommended starting point before trying retail discount programs. However, NovoCare is not available to Medicare or Medicaid beneficiaries, who must use their plan's formulary or a formulary exception process.
